A hospital is ending its liver transplant program after officials acknowledged in that doctors broke national standards by performing a transplant operation on a man who was not among the most needy patients. The patient in question was a Saudi Arabian citizen who was number-52 on the transplant list. Another patient, who was first on the list, died waiting for a donation.

St. Vincent Medical Center president and chief executive Gus Valdespino says continuing investigations into the 2003 transplant, the obstacles of salvaging the program ,and competitive pressures led to the decision t terminate the program

A hospital terminates its liver transplant program after officials admit doctors bypassed national standards by giving an organ to a man who has not at the top of a transplant list.

St. Vincent Medical Center president and chief executive Gus Valdespino says they have ended the program due to competitive pressures. The federal government has withdrawn its certification for the program, making the hospital ineligible to receive Medicare and Medicaid reimbursements for liver transplants

A new study reveals 8 out of 10 African Americans are unaware of the importance of speaking to their loved ones about their wish to become a donor.

In response to the study, The Links, Incorporated and Roche pharmaceutical company will distribute thousands of conversation starter guides at organ donor awareness church events nationwide on National Donor Sabbath, November 13

A new study reveals 8 out of 10 African Americans are unaware of the importance of speaking to their loved ones about their wish to become a donor.

In response to the study, The Links, Incorporated and Roche pharmaceutical company will distribute thousands of conversation starter guides at organ donor awareness church events nationwide on National Donor Sabbath, November 13

GlaxoSmithKline announces that the U.S. Food and Drug Administration (FDA) has approved Arranon (nelarabine) Injection, a chemotherapy agent, for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

According to GlaxoSmithKline, this use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted